US7665597024
US7665597024
Rigel Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 294.282.000 | 179.278.000 | 64.1% |
| Cost of Revenue | 19.621.000 | 18.647.000 | 5.2% |
| Gross Profit | 274.661.000 | 160.631.000 | 71.0% |
| 149.195.000 | 136.439.000 | 9.3% | |
| Operating Income | 125.466.000 | 24.192.000 | 418.6% |
| Pretax Income | 121.827.000 | 18.366.000 | 563.3% |
| Net Income Common Stockholders | 367.024.000 | 17.485.000 | 1999.1% |
| -- | -- | -- | |
| -- | -- | -- |